Volumetric

About Us

Volumetric is a recognized world leader in building living multicellular tissues, with a focus on replicating discrete functions of the human body for basic mechanistic biology, laboratory testing and screening, and drug development. Founded in 2018 by Bagrat Grigoryan and Jordan Miller as a spin-out from Rice University, the full potential of our work is to build whole human organ replacements for patients, made from their own cells.

Our Technology and Approach

We have invented a suite of breakthrough 3D bioprinting technologies, featured on the cover of Science, that can build human tissue with complex blood vessel networks. We are leveraging this technology in the short term to build patient-specific tissues for drug safety and efficacy testing. Patient cells are taken from a biopsy, added to our proprietary 3D printed tissues, and then drug compounds are injected through the blood vessel network to mimic actual drug delivery in humans. Our vision is that our technology will provide rigorous, reproducible, and predictive outcomes for patients, resulting in drastically improved outcomes for diseases like cancer. More broadly, we see the full potential of our mission as being able to produce functional tissue and organ replacements for diseased or damaged vital organs in the body such as the lung, liver, pancreas, kidney, and heart.

High-Level Overview

Volumetric Biotechnologies is a pioneering biotech company specializing in advanced 3D bioprinting technologies to build living multicellular tissues, with a focus on replicating discrete human body functions for applications in drug development, laboratory testing, and ultimately whole organ replacements. Their proprietary bioprinting platform enables the creation of vascularized human tissues with complex blood vessel networks, which can be seeded with patient cells to mimic real human drug delivery and biological responses. Founded in 2018 and based in Houston, Texas, Volumetric serves pharmaceutical companies, biomedical researchers, and the regenerative medicine field by providing more predictive and reproducible tissue models that address critical challenges in drug safety and efficacy testing. The company has demonstrated strong growth momentum, culminating in its acquisition by 3D Systems in 2021 for up to $400 million, positioning it as a key player in the emerging bioprinting and regenerative medicine ecosystem[1][2][4][5].

Origin Story

Volumetric was founded in 2018 by bioengineers Jordan Miller, PhD, and Bagrat Grigoryan, PhD, as a spin-out from Rice University. Miller, an expert in bioengineering and 3D bioprinting, and Grigoryan, with a strong background in tissue engineering, developed breakthrough bioprinting technologies capable of fabricating human tissues with integrated vascular networks. The idea emerged from their academic research aiming to overcome the limitations of existing tissue models and organ transplantation shortages by creating functional, patient-specific tissues and organs. Early traction included recognition in scientific journals such as *Science* and partnerships with leading life sciences companies. Their innovative approach attracted investment from notable firms including Y Combinator and 3D Systems, leading to the acquisition that expanded their R&D capabilities in Houston[2][3][4].

Core Differentiators

• Product Differentiators: Volumetric’s proprietary 3D bioprinting technology uniquely fabricates vascularized tissues with complex blood vessel networks, enabling realistic drug delivery and biological function replication.
• Developer Experience: The platform integrates patient-derived cells into bioprinted tissues, allowing personalized and predictive drug testing models.
• Speed and Ease of Use: Their vertically integrated bioprinting solutions streamline the production of organ-scale tissues, accelerating research timelines.
• Community Ecosystem: Strong ties with academic institutions like Rice University and partnerships with industry leaders such as 3D Systems and United Therapeutics foster a collaborative innovation environment.
• IP and Innovation: The company holds key patents related to bioprinting materials and methods, underpinning its technological leadership[1][2][4][5].

Role in the Broader Tech Landscape

Volumetric rides the cutting-edge trend of regenerative medicine and biofabrication, addressing the critical global need for organ replacements and improved drug development models. The timing is crucial as advances in 3D printing, biomaterials, and cell biology converge to make functional tissue engineering commercially viable. Market forces such as organ donor shortages, rising drug development costs, and regulatory demand for better preclinical models favor Volumetric’s technology. By enabling more accurate human tissue models and progressing toward whole organ bioprinting, Volumetric influences the broader ecosystem by pushing the boundaries of personalized medicine, reducing reliance on animal testing, and accelerating therapeutic innovation[2][4][5].

Quick Take & Future Outlook

Looking ahead, Volumetric is poised to expand its impact through continued R&D under 3D Systems’ umbrella, focusing on scaling organ replacement therapies and broadening applications in drug discovery and regenerative medicine. Trends such as personalized medicine, AI-driven tissue design, and increased regulatory acceptance of bioprinted tissues will shape their trajectory. Their influence is likely to grow as they help establish standards and commercial pathways for bioprinted organs, potentially transforming healthcare by reducing transplant waitlists and improving drug safety. Volumetric’s journey from academic spin-out to a key asset in a major 3D printing company underscores the transformative potential of bioprinting technologies in the next decade[4][5][6].